| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Jade Biosciences, Inc. (JBIO) has 2 insiders with recent SEC Form 4 filings, including 4 buys and 0 sells. JBIO is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 1.90M | $36.91M | - | |
| CFO | 526.0K | $10.23M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 2, 2021 | Sofinnova Venture Partners X, L.P.55 | 10% Owner | Buy | 357,142 | $14.00 | $4,999,988.00 | +10.5% | +5.2% | -15.1% | |
| Jul 2, 2021 | Atlas Venture Fund Xii, L.P. | 10% Owner | Buy | 535,714 | $14.00 | $7,499,996.00 | +20.9% | +5.2% | -15.1% | |
| Jul 2, 2021 | Grayzel David S. | Director | Buy | 535,714 | $14.00 | $7,499,996.00 | +20.9% | +5.2% | -15.1% | |
| Jul 2, 2021 | Katabi Maha71 | Director, 10% Owner | Buy | 357,142 | $14.00 | $4,999,988.00 | +10.5% | +5.2% | -15.1% |